부산대학교 도서관

Hofheinz RD; Bruix J; Demetri GD; Grothey A; Marian M; Bartsch J; Odom D

Cancer Management and Research, Vol Volume 13, Pp 5523-5533 (2021)

Rodriguez LR; U.S. Food and Drug Administration, Silver Spring, Maryland.; Gormley NJ; U.S. Food and Drug Administration, Silver Spring, Maryland.; Lu R; Alumis Inc., South San Francisco, California.; American Statistical Association, Alexandria, Virginia.; Amatya AK; U.S. Food and Drug Administration, Silver Spring, Maryland.; Demetri GD; Dana-Farber Cancer Institute, Boston, Massachusetts.; Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Mesa RA; Atrium Health, Winston-Salem, North Carolina.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina.; Pazdur R; U.S. Food and Drug Administration, Silver Spring, Maryland.; Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.; Shan M; Bayer, Whippany, New Jersey.; Snapinn S; Seattle-Quilcene Biostatistics LLC., Seattle, Washington.; Theoret MR; U.S. Food and Drug Administration, Silver Spring, Maryland.; Umoja R; American Association for Cancer Research, Washington, District of Columbia.; Vallejo J; U.S. Food and Drug Administration, Silver Spring, Maryland.; Warren NJH; American Association for Cancer Research, Washington, District of Columbia.; Xu Q; U.S. Food and Drug Administration, Silver Spring, Maryland.; Anderson KC; Dana-Farber Cancer Institute, Boston, Massachusetts.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Cote GM; Center for Sarcoma and Connective Tissue Oncology, Mass General Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Haddox CL; Harvard Medical School, Boston, Massachusetts.; Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Choy E; Center for Sarcoma and Connective Tissue Oncology, Mass General Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Merriam PA; Harvard Medical School, Boston, Massachusetts.; Mazzola E; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Venkataraman V; Harvard Medical School, Boston, Massachusetts.; Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Alcindor T; Harvard Medical School, Boston, Massachusetts.; Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Wagner AJ; Harvard Medical School, Boston, Massachusetts.; Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Demetri GD; Harvard Medical School, Boston, Massachusetts.; Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Ludwig Center at Harvard, Boston, Massachusetts.; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Boston, Massachusetts.; George S; Harvard Medical School, Boston, Massachusetts.; Sarcoma Division, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

D'Angelo SP; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: dangelos@mskcc.com.; Araujo DM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Abdul Razak AR; University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Agulnik M; City of Hope, Duarte, CA, USA.; Attia S; Mayo Clinic, Jacksonville, FL, USA.; Blay JY; Centre Léon Bérard, Lyon, France.; Carrasco Garcia I; Hospital Virgen del Rocío, Seville, Spain.; Charlson JA; Medical College of Wisconsin, Milwaukee, WI, USA.; Choy E; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Demetri GD; Dana Farber Cancer Institute, Boston, MA, USA; Ludwig Center at Harvard Medical School, Boston, MA, USA.; Druta M; Moffitt Cancer Center, Tampa, FL, USA.; Forcade E; Centre Hospitalier Universitaire de Bordeaux-Hôpital Haut-Lévêque, Bordeaux, France.; Ganjoo KN; Stanford Cancer Institute, Stanford Medicine at Stanford University, Palo Alto, CA, USA.; Glod J; Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.; Keedy VL; Vanderbilt University Medical Center, Nashville, TN, USA.; Le Cesne A; Institut Gustave Roussy Cancer Center-DITEP, Villejuif, France.; Liebner DA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; Moreno V; START Madrid-FJD, Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain.; Pollack SM; Northwestern University, Chicago, IL, USA.; Schuetze SM; University of Michigan Health System, Ann Arbor, MI, USA.; Schwartz GK; Columbia University Vagelos School of Medicine, New York, NY, USA.; Strauss SJ; UCL Cancer Institute, University College London NHS Foundation Trust, London, UK.; Tap WD; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.; Thistlethwaite F; The Christie NHS Foundation Trust, Manchester, UK; University of Manchester, Manchester, UK.; Valverde Morales CM; Hospital Universitari Vall d'Hebron, Barcelona, Spain.; Wagner MJ; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.; Wilky BA; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; McAlpine C; Adaptimmune, Abingdon, UK.; Hudson L; Adaptimmune, Abingdon, UK.; Navenot JM; Adaptimmune, Philadelphia, PA, USA.; Wang T; Adaptimmune, Philadelphia, PA, USA.; Bai J; Adaptimmune, Philadelphia, PA, USA.; Rafail S; Adaptimmune, Philadelphia, PA, USA.; Wang R; Adaptimmune, Abingdon, UK.; Sun A; Adaptimmune, Philadelphia, PA, USA.; Fernandes L; Adaptimmune, Philadelphia, PA, USA.; Van Winkle E; Adaptimmune, Philadelphia, PA, USA.; Elefant E; Adaptimmune, Philadelphia, PA, USA.; Lunt C; Adaptimmune, Abingdon, UK.; Norry E; Adaptimmune, Philadelphia, PA, USA.; Williams D; Adaptimmune, Philadelphia, PA, USA.; Biswas S; Adaptimmune, Abingdon, UK.; Van Tine BA; Washington University School of Medicine, St Louis, MO, USA.

Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Rubin BP; Blanke CD; Demetri GD; DeMatteo RP; Fletcher CDM; Goldblum JR; Lasota J; Lazar A; Maki RG; Miettinen M; Noffsinger A; Washington MK; Krausz T; College of American Pathologists. Cancer Committee (CORPORATE AUTHOR)

Archives of Pathology & Laboratory Medicine. Feb2010, Vol. 134 Issue 2, p165-170. 6p.

Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG; Demetri, George D; van Oosterom, Allan T; Garrett, Christopher R

Lancet. 10/14/2006, Vol. 368 Issue 9544, p1329-1338. 10p.

Kummar S; Stanford Cancer Center, Stanford University, Palo Alto, California, USA.; Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Hong DS; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; McDermott R; St. Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.; Keedy VL; Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Casanova M; Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Demetri GD; Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, USA.; Dowlati A; University Hospitals Ahuja Medical Center, Beachwood, Ohio, USA.; Melcón SG; Pediatric Oncology and Hematology, Vall d'Hebron Children's Hospital, Barcelona, Spain.; Lassen UN; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.; Leyvraz S; Charité-Universitätsmedizin Berlin, Berlin, Germany.; Liu T; Zhongshan Hospital-Fudan University, Shanghai, China.; Moreno V; START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.; Patel J; Northwestern University, Chicago, Illinois, USA.; Patil T; Department of Medicine, Division of Medical Oncology, University of Colorado, Aurora, Colorado, USA.; Mallick AB; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Sousa N; Instituto Portugues de Oncologia do Porto Francisco Gentil, Porto, Portugal.; Tahara M; National Cancer Center Hospital East, Kashiwa, Japan.; Ziegler DS; Sydney Children's Hospital, Randwick, New South Wales, Australia.; Australia and School of Women's and Children's Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.; Norenberg R; Chrestos Concept GmbH & Co. KG, Essen, Germany.; Arvis P; Bayer Pharmaceuticals, Loos, France.; Brega N; Bayer Pharmaceuticals, Milan, Italy.; Drilon A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Weill Cornell Medical College, New York, New York, USA.; Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore.

Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Heinrich MC; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Corless CL; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Demetri GD; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Blanke CD; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; von Mehren M; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Joensuu H; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; McGreevey LS; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Chen CJ; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Van den Abbeele AD; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Druker BJ; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Kiese B; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Eisenberg B; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Roberts PJ; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Singer S; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Fletcher CDM; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Silberman S; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Dimitrijevic S; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.; Fletcher JA; From the Oregon Health and Science University Cancer Institute, Oregon Health and Science University, and Portland Veterans Affairs Medical Center, Portland, OR; Dana-Farber Cancer Institute and Harvard Cancer Center, Boston, MA; Fox-Chase Cancer Center, Philadelphia, PA; University of Turku, Turku; University of Helsinki, Helsinki, Finland; and Novartis Oncology, Basel, Switzerland.

Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: PubMed not MEDLINE; MEDLINE

Bevill SM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Casaní-Galdón S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; El Farran CA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Cytrynbaum EG; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.; Macias KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Oldeman SE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Oliveira KJ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Moore MM; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Hegazi E; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.; Adriaens C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Najm FJ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Demetri GD; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.; Cohen S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.; Mullen JT; Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.; Riggi N; Department of Cell and Tissue Genomics (CTG), Genentech Inc, South San Francisco, CA 94080, USA.; Johnstone SE; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Bernstein BE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Departments of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02115, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.

Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918284260106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-979X (Electronic) Linking ISSN: 2666979X NLM ISO Abbreviation: Cell Genom Subsets: PubMed not MEDLINE

Neel DV; Harvard Medical School, Boston, Massachusetts, USA.; Ma C; Centre for Addiction and Mental Health, Toronto, Ontario, Canada.; Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.; Collins NB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.; Hornick JL; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Demetri GD; Harvard Medical School, Boston, Massachusetts, USA.; Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, Massachusetts, USA.; Shulman DS; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE